Exscientia PLC is a United Kingdom-based artificial intelligence-driven pharmaceutical technology company. The Company is focused on discovering, designing and developing the possible drugs. The Company has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress artificial intelligence (AI) designed small molecules into the clinical setting. The Company’s AI process is comprised of five elements, including Precision Target, Precision Design, Precision Experiment, Precision Medicine and Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the experimental underpinnings for AI-design. The Company's lead drug candidate, EXS21546, is in early stage of development.
Buy US stocks in Australia starting with EXAI. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in EXAI
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.